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Abstract
Background: Brain metastases occur in 30-50% of Non-small cell lung cancer (NSCLC) patients and confer a worse
prognosis and quality of life. These patients are usually treated with Whole-brain radiotherapy (WBRT) followed by
systemic therapy. Few studies have evaluated the role of chemoradiotherapy to the primary tumor after WBRT as
definitive treatment in the management of these patients.
Methods: We reviewed the outcome of 30 patients with primary NSCLC and brain metastasis at diagnosis without
evidence of other metastatic sites. Patients were treated with WBRT and after induction chemotherapy with
paclitaxel and cisplatin for two cycles. In the absence of progression, concurrent chemoradiotherapy for the
primary tumor with weekly paclitaxel and carboplatin was indicated, with a total effective dose of 60 Gy. If disease
progression was ruled out, four chemotherapy cycles followed.
Results: Median Progression-free survival (PFS) and Overall survival (OS) were 8.43 ± 1.5 and 31.8 ± 15.8 months,
respectively. PFS was 39.5% at 1 year and 24.7% at 2 years. The 1- and 2-year OS rates were 71.1 and 60.2%,
respectively. Three-year OS was significantly superior for patients with N0-N1 stage disease vs. N2-N3 (60 vs. 24%,
respectively; Response rate [RR], 0.03; p= 0.038).
Conclusions: Patients with NSCLC and brain metastasis might benefit from treatment with WBRT and concurrent
thoracic chemoradiotherapy. The subgroup of N0-N1 patients appears to achieve the greatest benefit. The result of
this study warrants a prospective trial to confirm the benefit of this treatment.
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Introduction
Brain metastases occur in 30-50% of patients with Non-
small-cell lung cancer (NSCLC) and confer upon the
patient a worse prognosis and quality of life [1-6]. Med-
ian survival of patients who receive supportive care and
are treated only with corticosteroids is approximately 1-
2 months [2]. Primary approaches to the treatment of
brain metastases include Whole-brain radiation therapy
(WBRT), surgery, stereotactic radiosurgery, or a
combination, which have achieved a median survival
time that ranges from 6.5-10 months [7-11].
As improvements are made in the management of
brain metastases, the question arises on how to manage
patients with NSCLC who have solely stable brain meta-
static disease and on whether treatment should be con-
sidered for the primary lung lesion. Long-term survival
has been achieved in some patients who have undergone
either cranial surgery or radiotherapy and aggressive
thoracic management with lung tumor resection, with
studies reporting 5-year survival rates between 10 and
20% [12-16]. Few studies have evaluated the role of
thoracic radiation or chemoradiotherapy as definitive
* Correspondence: ogar@servidor.unam.mx
1Clinic of Thoracic Oncology, Instituto Nacional de Cancerología (INCan),
Mexico City, Mexico
Full list of author information is available at the end of the article
Arrieta et al. Radiation Oncology 2011, 6:166
http://www.ro-journal.com/content/6/1/166
© 2011 Arrieta et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.treatment in the management of patients with NCSLC
and synchronous solitary brain metastasis, and some of
these have shown promising results [17,18]. Despite
these findings, the majority of patients are only offered
chemotherapy or radiation therapy in a palliative man-
ner [18].
In an effort to clarify such conflicting data and in
order to identify patients who may benefit from
aggressive management, we reviewed the outcome of
30 patients with either unresectable single or multiple
brain metastases treated with WBRT, who were
managed subsequently with definitive thoracic
chemoradiotherapy.
Methods
In a retrospective review of patients treated at the Insti-
tuto Nacional de Cancerología (INCan) in Mexico City
from May 2005 to March 2009, we identified 30 patients
with histologically proven NSCLC and synchronous
brain metastases. All patients selected for this analysis
had the following characteristics: (1) synchronous diag-
nosis of NSCLC and brain metastasis (within 2 months
of the lung primary diagnosis); (2) absence of neoplastic
spread elsewhere in the body at the time of NSCLC and
brain metastases detection, and (3) patients with either
one unresectable lesion or multiple brain metastases,
who were not candidates for surgery or stereotactic
radiosurgery treated with WBRT.
Patients’ hospital records and office charts were
reviewed. Variables collected for analysis included age,
gender, Karnofsky performance status (KPS), Radiation
Therapy Oncology Group Recursive partitioning analysis
(RPA) class, primary Tumor-node-metastasis staging
(TNM, according to the American Joint Committee on
Cancer Staging Manual, sixth edition [19]), primary his-
tology, and number of brain metastases.
Diagnosis of brain metastases was made based on
brain imaging using either Computed tomography (CT)
or Magnetic resonance imaging (MRI). These studies
were obtained as a routine staging procedure or in the
evaluation of suspicious symptomatology. Thoracic stage
and nodal status were determined by means of chest
Computed tomography (CT) with or without Positron
emission tomography (PET) imaging.
Treatment plan
Whole-brain radiotherapy
Conventional megavoltage external beam radiotherapy
was administered with a linear accelerator (energy 6
MV) or with a cobalt bomb (1.25 MV). For WBRT, two
lateral opposed fields were used, covering up to C2 ver-
tebral body. Dose administered was 30 Gy/10 fractions.
Once patients received WBRT, systemic chemotherapy
was started.
Systemic and thoracic treatment
Initially, two cycles of systemic chemotherapy were
administered with paclitaxel 175 mg/m
2 Intravenously
(IV) > 3 h and cisplatin 75 mg/m
2 IV on day 1 every 21
days. Following response assessment after the first two
cycles of chemotherapy and in the absence of progres-
sion either at the primary lung tumor or Central ner-
vous system (CNS), chemoradiotherapy was indicated.
Thoracic radiotherapy was administered with a linear
accelerator (energy 6 and/or 15 MV), and the treatment
volume for the primary tumor was based on initial diag-
nosis volume. The ipsilateral hilum was treated for N0-
N2 disease, while for N3, the contralateral hilum was
also included. Clinical target volume (CTV) included
gross tumor volume plus 2-cm margin and the dose to
the primary tumor was 60 Gy (BED).
Concurrently with radiotherapy, weekly paclitaxel 60-
80 mg/m
2 and carboplatin at a dose of AUC 2, accord-
ing to Calvert, were administered. If disease progression
was ruled out, four chemotherapy cycles followed, using
the same schedule as that of the induction regimen.
Response assessment
Follow-up for primary disease was performed with CT,
generally every 2 months. Follow-up for brain metas-
tases was conducted by MRI, usually every 2 months.
All patients were evaluated according to Response Eva-
luation Criteria in Solid Tumors (RECIST) criteria every
two cycles: Complete response was defined as resolution
of all disease, partial response constituted a 30%
decrease in the sum of the longest diameter of target
lesions, progressive disease was defined as 20% increase
in the sum of the longest diameter of target lesions, and
stable disease comprised neither sufficient shrinkage to
qualify for partial response nor sufficient increase to
qualify for progressive disease. Response assessment was
performed before chemoradiotherapy was indicated.
Statistical analysis
For descriptive purposes, continuous variables were sum-
marized as arithmetic means and Standard deviation (SD),
and categorical variables as relative frequencies and propor-
tions. Progression-free survival (PFS) was calculated from
date of diagnosis of NSCLS until progression. Overall survi-
v a l( O S )w a sd e f i n e da st i m ef r o md i a g n o s i so fN S C L S
until death or until the patient was censored at time of last
follow-up. Median time to progression, median probability
of survival, and 1- and 2-year survival rates were estimated
by the Kaplan-Meier method. Significance value was set at
p < 0.05. SPSS software package version 17 (SPSS, Inc.,
Chicago, IL, USA) was employed to analyze the data.
Results
Patient Characteristics
Patient characteristics are summarized in Table 1. Med-
ian patient age at time of diagnosis was 57 years, and
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documented in 76.7% of patients. The majority of
patients had an Eastern Cooperative of Gynecologists
(ECOG) performance status of 0 or 1 (90%). The most
common histology was adenocarcinoma (80%), and all
patients were RPA 2 class. Twenty patients (66.7%) were
evaluated with PET CT to rule out other sites of meta-
static disease. The number of brain metastatic lesions
varied between 1 and 5, with a median of three CNS
metastases.
Response
With regard to response after WBRT, all patients
received the planned radiotherapy dose. Twelve patients
(40%) had stable disease, nine patients (30%) achieved
partial response, and nine (30%) presented complete
response. Median number of chemotherapy cycles was
six. Five patients did not receive the planned cycles
(17%). When primary tumor response was assessed, 18
patients (60%) achieved a partial response and 12
patients (40%) had stable disease.
Outcome
Median follow-up was 10.2 ± 2 months. Median PFS
and OS were 8.43 ± 1.5 months and 31.8 ± 15.8 months,
respectively [Figures 1A and 1B]. PFS was 39.5% at 1
year and 24.7% at 2 years. Fifteen patients (50%) had
local progression, whereas 10 (33%) developed distant
sites of metastases. The 1- and 2-year OS rates were
71.1 and 60.2%, respectively. Three-year OS was signifi-
cantly superior for patients with N0-N1 stage disease vs.
N2-N3 (60 vs. 24%, respectively; RR, 0.03; p =0 . 0 3 8 )
[Figure 2]. In a univariate analysis using the Log Rank
test, there was no statistically significant difference in
survival according to age (p = 0.07), KPS (p =0 . 5 ) ,g l o -
bal response (p = 0.7), history of smoking (p = 0.4), and
histology (p = 0.17).
Discussion
A considerable proportion of patients with NSCLC
develop brain metastases at some point during their dis-
ease course and this generally leads to a poor prognosis.
However, in some cases, long-term survival has been
achieved after aggressive therapy of cerebral lesions,
Table 1 Baseline characteristics of patients and disease
Median age (years) 57 ± 11.1
Gender (Female) 17 (56.7%)
ECOG
0 8 (26.7%)
1 19 (63.3%)
2 3 (10%)
Comorbidities
EPOC 4 (13.3%)
Diabetes 3 (10%)
Hypertension 3 (10%)
Histology
Adenocarcinoma 24 (80%)
Squamous 4 (13.3%)
Other 2 (6.7%)
Smoking history
Yes 23 (76.7%)
No 7 (23.3%)
Nodal status
N 0-1 (n) 16 (53.3%)
N 2-3 (n) 14 (46.7%)
RPA class 2 30 (100%)
Median brain metastatic lesions 3±2
ECOG: Eastern Cooperative of Gynecologists; RPA: Radiation Therapy Oncology
Group Recursive partitioning analysis (RPA).
Figure 1 A) Kaplan-Meier Progression-free survival (PFS) curve
for patients with NSCLC treated with WBRT and concurrent
chemoradiotherapy (n = 30). B) Kaplan-Meier Overall survival (OS)
curve for patients with NSCLC treated with WBRT and concurrent
chemoradiotherapy (n = 30).
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vival rates ranging from 10-25% [7,8,20,21].
As improvements are made in the management of
patients with brain metastases without extracranial dis-
ease, the question arises of how to treat the primary
lung cancer. This is due to the fact that the main cause
of death in patients with lung carcinoma treated aggres-
sively for brain metastases is progression of the primary
cancer [13,22].
In a recent review of the literature, Modi et al. identi-
fied 11 papers that addressed the issue of surgical resec-
tion of the primary tumor within the context of
metastatic brain lesions [23]. They found that median
survival for curative intent groups (combined therapy
w i t ho rw i t h o u ta d j u v a n tt r e a t m e n t )r a n g e df r o m1 9 - 2 7
months (mean, 23.12 ± 3.3 months) and 1-, 2-, and 5-
year OS reached 56-69%, 28-54%, and 11-24%, respec-
tively. The authors concluded that in the absence of
mediastinal lymph node involvement, surgical resection
of NSCLC with complete resection of the brain metasta-
sis improves prognosis. Furthermore, they described that
some features such as adenocarcinoma histology, low
carcinoembryonic antigen (CEA) levels at presentation,
response to preoperative chemotherapy before local
treatment, and high KPS score may have a positive
prognostic value.
The benefit of surgical resection after induction ther-
apy compared with definitive radiotherapy remains
uncertain and appears to be associated with an increase
in early surgery-associated mortality. The Intergroup
0139 [24] and the EORTC 08941 [25] did not confirm a
significant survival advantage for surgery following
either neoadjuvant concurrent chemoradiotherapy or
induction chemotherapy. Thus, we opted to treat our
patients with NSCLC with brain metastases with
definitive chemoradiotherapy as an alternative to a more
aggressive surgical approach.
To our knowledge, five different studies have reported
their results in patients with NSCLC with synchronous
brain metastatic disease treated with radiotherapy
[13,16-18,26] and/or chemoradiotherapy [17,18] to the
primary tumor, but the majority of these studies also
included patients treated with other modalities, such as
surgical resection of the thoracic lesion [13,16,18] or
solely chemotherapy [17]. Brain management differed
significantly among these series, and included surgical
resection of brain metastases, WBRT, stereotactic sur-
gery, or a combination of the former. Median OS times
varied between 5.2 and 18 months, with 1- and 2-year
survival rates that ranged between 22-71.3% and 10-
34.1%, respectively. For patients treated with definitive
thoracic therapy after brain metastases management
with gammaknife stereotactic radiosurgery, Flannery et
al. reported significantly better survival than those that
did not receive definitive treatment (median OS, 26.4 vs.
13.1 months). In our series, we reached a median survi-
val of 31.8 months, the longest survival reported to date
in patients with synchronous brain metastatic disease
treated with definitive chemoradiation to the primary.
Unlike other studies, in our report, treatment delivered
to the brain, as well as systemic and local therapy, was
homogeneous among all patients included.
By applying American Joint Committee on Cancer
(AJCC) staging only to the primary site, Hu et al.
reported that patients with thoracic stage I had a more
favorable outcome, with a median survival time of 25.6
months (compared with 9.5 and 9.9 months for stages II
and III, respectively), and concluded that aggressive
treatment to the lung may be justified for newly diag-
n o s e dt h o r a c i cs t a g eIN S C L Cw i t has o l i t a r yb r a i n
metastasis [17]. Also, Louie et al. reported longer overall
survival for stage I/II disease of 14.7 months compared
with 7 months for patients with stage III NSCLC with
synchronous solitary brain metastasis treated with cra-
niotomy and WBRT [16]. In our study, according to the
univariate analysis, we found that patients with N0-N1
disease had a significantly better 3-year survival rate
compared with those with N2-N3 disease. Similar find-
ings have been reported in previous studies where the
absence of mediastinal lymph node involvement (N2) is
one of the most important survival determinants
[15,27,28]. Accordingly, in patients with controlled brain
d i s e a s ea n de a r l yl u n gd i s e a s e( N 0 - N 1 )a m e n a b l et o
resection, a conservative surgery of the primary tumor
may be the best treatment alternative (segmentectomy
or lobectomy). For patients who are not candidate for
surgical resection, chemoradiatiation to the primary
tumor should be considered. In Table 2, we condensed
the studies that assessed radiation therapy or
Figure 2 Overall survival (OS) for patients with NSCLC treated
with WBRT and concurrent chemoradiotherapy.
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patients with central nervous metastatic disease.
To our knowledge, this is the first time that patients
with multiple synchronous brain metastases treated with
WBRT have been managed with aggressive therapy for
primary tumor in chest with concurrent chemora-
diotherapy, showing a very long OS. Among series that
evaluated surgery as local treatment for the thoracic dis-
ease, several included patients with multiple brain
metastases [12,28-32]. In none of these studies was the
number of brain lesions described as a factor that con-
ferred poor prognosis.
Other prognostic factors associated with better out-
comes with this definitive strategy after treatment to the
brain disease are younger age [31,33], early stage nodal
disease [15-17,27,28,31], good performance status
[18,30-32,34], adenocarcinoma subtype [14,28,32,35],
location of primary tumor, site of brain metastases, and
low CEA levels [28,36].
Median survival in patients treated in this series is
remarkably long. One of the reasons might be that we
selected patients who presented with synchronous brain
tumors and did not include those with metachronous
lesions, which may represent a better prognostic group.
In addition, we selected patients who did not progress
after induction chemotherapy to proceed with further
thoracic management, in order to ensure that patients
with rapid progressive metastatic disease would not be
submitted to a more aggressive management instead of
a palliative approach. Furthermore, the majority of
patients were assessed with PET-CT at diagnosis, which
reduces the likelihood of metastatic disease elsewhere,
Table 2 Series evaluating radiation therapy or chemoradiotherapy of lung cancer in NSCLC with brain metastasis
Study Year Number of
patients
Number of
brain
metastases
Brain
treatment
Median
survival,
months
1-year
survival
rate (%)
2-year
survival
rate (%)
5-year
survival
rate (%)
Prognostic factors
Chidel et al.
[13]
1999 Sx = 2
Sx + RT = 3
RT = 8
Palliative =
15
1S x
WBRT
STS
and
combination
Overall: 6.9
Definitive tx:
20.1
No definitive
tx: 3.5
12 (3-year) WBRT
Aggressive thoracic
treatment
Moazami et
al.[31]
2002 Chemo/RT
=2 9
Sx = 59
42 pts: 1
49 pts: > 1
Metachronous
brain lesions
Sx
WBRT
STS
and
combinations
5.2 22 10 - Younger age
Stage IIIA
Lung resection
ECOG
No extracranial mets
Sx of brain mets
STS
Hu et al.[17] 2006 RT = 44
Chemo =
23
Chemo/RT
=1 3
1S x
STS
Overall: ~15
Stage I: 25.6
Stage II: 9.5
Stage III: 9.9
49.8 16.3 7.6 Thoracic stage I
Ampil et al.
[26]
2007 > 65 year
RT = 22
No RT = 50
1 WBRT
STS
Sx
and
combinations
RT = 5
No RT = 3
p = 0.28
RT = 14
No RT = 11
p= 0.28
- - Sx of brain mets
Flannery et al.
[18]
2008 RT = 26
Chemo/RT
=9
Sx = 12
Preop
Chemo +
Sx = 5
1 STS Overall: 18
Definitive tx:
26.4
No definitive
tx: 13.1
p < 0.0001
Overall: 71.3 Overall: 34.1 Overall: 21
RT: 34.6
No RT: 0
p < 0.0001
Definitive thoracic
therapy
KPS
Louie et al.
[16]
2009 Sx = 8
Chemo =
24
RT = 14
1 Sx + WBRT 7.8
Stage I/II:
14.7
Stage III: 7
- - - Lung surgery
a
Primary lung
treatment
a
> 8 weeks after brain
Sx
a
Stage I/II disease
a
Arrieta et al.
(present
series)
2010 Chemo-
Chemo/RT
=3 0
> 1 WBRT 31.8 71.1 60.2 3-year OS for N0-1
was 60 vs. 24% for
N2-3
NSCLC: Non-small-cell lung cancer; Sx: Surgery; RT: Radiotherapy; WBRT: Whole-brain radiotherapy; STS: Stereotactic surgery; Comb: Combination; Mets:
Metastasis/Metastases; Chemo: Chemotherapy; Chemo/RT: Chemo-radiotherapy; Preop: Pre-operative. a) Univariate analysis.
Arrieta et al. Radiation Oncology 2011, 6:166
http://www.ro-journal.com/content/6/1/166
Page 5 of 7compared with routine evaluation with CT and bone
scan [37]. Finally, a high proportion of patients had
stage 0-1 nodal disease (53.3%) and 0-1 ECOG grade
(90%) and with few comorbidities, which might suggest
that this therapeutic approach should be reserved for
otherwise healthy patients with non-bulky mediastinal
lymph node involvement.
Conclusion
Patients with NSCLC and synchronous brain metastases
might benefit from aggressive treatment with WBRT
and concurrent chemoradiotherapy to the primary
lesion, particularly in well-selected patients. The result
of this study warrants a prospective trial in stage IV dis-
ease with only brain metastasis to confirm the benefit of
this treatment.
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